Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Varnimcabtagene Autoleucel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Taiba Healthcare
Deal Size : $12.0 million
Deal Type : Financing
Taiba Makes Strategic Investment in Immuneel Therapeutics to Advance CAR T-cell Research
Details : The intended to advance CAR T-cell research development of Phase 2 trial for CD19 CAR-T IMN-003A (varnimcabtagene autoleucel) targeting B-cell malignancies, including leukemia and lymphoma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 30, 2024
Lead Product(s) : Varnimcabtagene Autoleucel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Taiba Healthcare
Deal Size : $12.0 million
Deal Type : Financing
Immuneel's CAR-T Cell Therapy Reports Positive In Early Phase-2 Trials In India
Details : IMN-003A (varnimcabtagene autoleucel) has demonstrated early, deep and durable remission in children and adults with relapsed / refractory B cell malignancies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Autologous T Cell
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Hospital Clinic of Barcelona
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Immuneel, HCB and IDIBAPS Enter into a Collaboration and Licensing Agreement for CAR T Cell Therapy
Details : Immuneel acquires exclusive rights to develop and commercialise autologous ARI-0001 – a CD19 Chimeric antigen receptor (CAR) T cell therapy, in India.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : Autologous T Cell
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Hospital Clinic of Barcelona
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
